🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📰In a retrospective real🌐analysis, published by HemaSphere Journal (IF = 11.9), conducted at 21 German Centers, including 138 RRMM patients treated with talquetamab, of evaluable pts, 43%➡️ISS stage III, 37% had extraosseous disease & 48% had⬆️risk cytogenetics READ➡️pubmed.ncbi.nlm.nih.gov/40248128/

🚨Posttransplant lymphoproliferative disorders (PTLDs) are a serious complication of transplantation, with diffuse large B-cell lymphoma (PT-DLBCL) being the most common subtype. This review explores PT-DLBCL pathogenesis and highlights the importance of improved diagnostics and

The EXALT-2 trial (NCT04470947) demonstrates feasibility of integrating genomic-based & drug screening-based precision medicine strategies into clinical routines for R/R blood cancer patients. Both methodologies efficiently guide therapy decisions for the majority of patients

This HemaTopic by Sci Ed C de Bock discusses the use of PDXs in testing new therapies for leukemia, highlighting the establishment & maintenance of PDX models, the role of immunodeficient mice & the importance of standardized reporting for preclinical drug testing. It also ties

Happy to share the results of the Nordic biomarker-adapted trial in patients with high-risk LBCL (NLG-LBC-06) just released online in HemaSphere Journal (IF = 11.9) at onlinelibrary.wiley.com/doi/10.1002/he… We learned that prospective stratification according to biological risk factors is feasible.

New research identifies the FDA/EMA-approved drug spironolactone as a specific inhibitor of the NLRP1 inflammasome, alleviating defective erythropoiesis in Diamond-Blackfan anemia. 👉bit.ly/4jIYUVJ IIC-UMU-IMIB 🇺🇦🇺🇦🇺🇦 #DBA #Inflammasome

This article published in our April issue discusses significant improvements in post-transplant outcomes for patients with Ph+ ALL over time. It highlights the decrease in relapse and non-relapse mortality rates, the increase in leukemia-free survival & overall survival

The French Hematology Society's GBMHM network enhances molecular diagnostics for hematological cancers. This Perspective highlights efforts for hemato-oncology molecular diagnostics to adapt to the 2017/746 IVDR regulation. Read more 👉bit.ly/3XPgfUy

Authors discuss targeting metabolism to eradicate leukemic stem cells (LSCs) in #AML. This paper highlights the role of LPIN1 in regulating diacylglycerol synthesis, its high expression in AML samples, and the anti-leukemic activity of choline kinase inhibitors Read more

Axicel in second line DLBCL: are we really moving the line? Read this recently published Review here 👉bit.ly/4hLagqR Vadim Lesan

Authors discuss the challenges in treating elderly patients with classical Hodgkin lymphoma and the promising results of brentuximab vedotin (BV) monotherapy. BV shows efficacy and manageable toxicity, making it a viable first-line treatment option for this patient group #cHL

This recent paper discusses how hepatocytes directly recognize pathogens and upregulate hepcidin, independent of macrophage cytokine secretion. This positions hepatocytes as potential direct drivers of iron restriction during infections. Read more here 👉bit.ly/3XNL6km

This multicenter study validates the ELN Scoring System for diagnosing MDS. It highlights high sensitivity, especially in low-risk MDS cases, and its potential for broad clinical application due to its simplicity and diagnostic accuracy. Read more about it in

Authors discuss the efficacy of daratumumab-based therapies versus CyBorD for newly diagnosed AL amyloidosis with IIIb cardiac stage. Daratumumab shows ⬆️ rates of hematologic and cardiac response, leading to prolonged OS, stressing the need for broader access to this treatment.

Just published! Quick diagnosis, modern treatments, psychosocial support ➕. These standards are what every patient deserves. The European Cancer Organisation and the European Hematology Association identified a list of essential standards for all healthcare systems in Europe.

📖HemaSphere's May issue is complete 👉bit.ly/453egQN and as always, is 100% #OpenAccess. Please enjoy reading these quality publications & feel free to share with your networks. #hematology #lymphsm #CART #hematopoiesis #EHAClinicalGuidelines #metabolism #leusm

📣HemaSphere's June issue is now open and already hosts a pub about new horizons in the management of #VenousThromboembolism; & a retrospective study on efficacy of tx in #VEXAS. Plus lots more coming soon - we launch new pubs regularly. Have a browse 👉bit.ly/4jvZi9p

The next HemaSphere podcast is coming soon!  Host Dr Charles de Bock is back, this time with Dr Francesca Fioredda and Dr Eleni Papadaki, discussing the newest treatment Guidelines for neutropenia.  How long do these Guidelines really take?